** Shares of drugmaker MannKind rise 2.1% to $6.81 premarket
** MNKD and partner Cipla say the Central Drugs Standard Control Organisation (CDSCO) in India has approved MNKD's insulin inhalation powder Afrezza
** India has the second highest burden of diabetes worldwide the companies say
** MNKD expects to ship product for CIPL by end of 2025
** Under the agreement, CIPL is responsible for obtaining regulatory approvals to distribute Afrezza in India as well as marketing and sales activities, while MNKD is responsible for supplying it
** Up to last close, MNKD up 83.2% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。